Gelonghui, March 28, 丨 Lemei Pharmaceutical (300006.SZ) announced that recently, Chongqing Laimei Pharmaceutical Co., Ltd. participated in a self-developed macrophage CUD005 injection (“CUD005 injection”) of Sichuan Kangdesai Medical Technology Co., Ltd. (“CUD005 injection”), a self-developed macrophage cell CUD005 injection (“CUD005 injection” for short) to treat decompensated liver cirrhosis, obtained implied approval for drug clinical trials and obtained the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration.
Cirrhosis of the liver is a common chronic progressive tissue damage liver disease. The causes include long-term alcohol abuse, obesity, metabolic disorders, viral infections, or autoimmune diseases. Cirrhosis damages the normal tissue structure of the liver, leading to loss of liver function, and fibrosis scars.
CUD005 injection is based on the patient's autoimmune cells, which are differentiated into mature and stable individualized anti-fibrotic macrophages, which can degrade extracellular matrices and reduce liver scarring by secreting various matrix metalloproteinases. Furthermore, CUD005 injection can release anti-inflammatory factors, thereby inhibiting the occurrence of inflammatory reactions, improving the microenvironment of liver inflammation, and slowing the progression of the condition.